Biogennix, Inc., the Irvine, California-based osteobiologic company, has named Robert Baizer its new Chief Financial Officer.
Biogennix Names Robert Baizer CFO
1 min read Premium comments
Secondary#biogennix#robertbalzer
Biogennix is the developer, manufacturer, and distributor of proprietary bone graft substitutes for bone fusion procedures. Its osteoSPAN and Morpheus bone graft substitutes are resorbable, osteoconductive scaffolds that are designed for bone regeneration and optimal handlings by surgeons.
Baizer joins Biogennix with over 25 years of professional finance experience. The last 10 years of his career have been focused on the biotechnology sector. His most recent role was leading the private equity group that partnered with Qualcomm, Inc. to develop a suite of wireless medical devices.
Michael Roux, Biogennix’s General Manager, said, “We are pleased to have Robert as a new key member of our Biogennix leadership team. Robert is a great fit and brings strong business, medical device and financial leadership experience to our team, further positioning us for continued growth.”
Robert Baizer told OTW, “It’s great to be working as part of the terrific Biogennix team, and I am looking forward to putting my background in medical device finance to good use as we enter the next stage of the company’s growth. The team has done an impressive job to date, and with that foundation of success, strategic finance will now play an important role in taking the company to the next level. I am excited to be leading that effort.”
Baizer’s appointment comes just as Biogennix has reported that its products have now been used in more than 11,000 patients. This is an increase of more than 5,000 patients since Q4 of 2017.
“We’re proud that our osteoSPAN and Morpheus bone graft products have been so well received by the clinician and patient communities and that we’ve been able to contribute to such positive post-op outcomes for more than 11,000 spine surgery patients,” said Clay Shors, Biogennix’s President. “We firmly believe that our products are fast becoming the new standard of effectiveness and ease of use when it comes to bone graft substitutes.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.